## Teresinha Evangelista

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3032009/publications.pdf

Version: 2024-02-01

69 papers 2,150 citations

186265 28 h-index 243625 44 g-index

74 all docs

74 docs citations

74 times ranked 3291 citing authors

#	Article	IF	CITATIONS
1	Localization of merosin-negative congenital muscular dystrophy to chromosome 6q2 by homozygosity mapping. Human Molecular Genetics, 1994, 3, 1657-1661.	2.9	214
2	A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 456-460.	2.1	101
3	Nocturnal pulse oximetry: a new approach to establish the appropriate time for nonâ€invasive ventilation in ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 31-35.	1.2	95
4	Can amyotrophic lateral sclerosis patients with respiratory insufficiency exercise?. Journal of the Neurological Sciences, 1999, 169, 69-75.	0.6	88
5	Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. Brain, 2014, 137, 2429-2443.	7.6	86
6	Genetic heterogeneity of motor neuropathies. Neurology, 2017, 88, 1226-1234.	1.1	81
7	Sleep characteristics of amyotrophic lateral sclerosis in patients with preserved diaphragmatic function. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 101-105.	2.1	75
8	Mutations in the Mitochondrial Citrate Carrier SLC25A1 are Associated with Impaired Neuromuscular Transmission. Journal of Neuromuscular Diseases, 2014, 1, 75-90.	2.6	69
9	Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology, 2016, 87, 295-298.	1.1	60
10	Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. Journal of Neurology, 2008, 255, 545-550.	3.6	51
11	Reduced serum myostatin concentrations associated with genetic muscle disease progression. Journal of Neurology, 2017, 264, 541-553.	3.6	51
12	Molecular characterization of congenital myasthenic syndromes in Spain. Neuromuscular Disorders, 2017, 27, 1087-1098.	0.6	51
13	Phrenic nerve conduction in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 1995, 129, 35-37.	0.6	45
14	Identification of mutations in the <i>MYO9A </i> Brain, 2016, 139, 2143-2153.	7.6	45
15	Exome sequences versus sequential gene testing in the UK highly specialised Service for Limb Girdle Muscular Dystrophy. Orphanet Journal of Rare Diseases, 2017, 12, 151.	2.7	44
16	The Increasing Genetic and Phenotypical Diversity of Congenital Myasthenic Syndromes. Neuropediatrics, 2017, 48, 294-308.	0.6	43
17	Dominant and recessive <i>RYR1</i> mutations in adults with core lesions and mild muscle symptoms. Muscle and Nerve, 2011, 44, 102-108.	2.2	39
18	Complex phenotypes associated with STIM1 mutations in both coiled coil and EF-hand domains. Neuromuscular Disorders, 2017, 27, 861-872.	0.6	39

#	Article	IF	CITATIONS
19	Liver and Muscle in Morbid Obesity: The Interplay of Fatty Liver and Insulin Resistance. PLoS ONE, 2012, 7, e31738.	2.5	38
20	215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13–15 November 2015, Heemskerk, The Netherlands. Neuromuscular Disorders, 2016, 26, 535-547.	0.6	38
21	Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long-term follow-up of 19 patients. Journal of Neurology, 2018, 265, 194-203.	3.6	36
22	New variants, challenges and pitfalls in DMD genotyping: implications in diagnosis, prognosis and therapy. Journal of Human Genetics, 2014, 59, 454-464.	2.3	35
23	Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2018, 57, 380-387.	2.2	33
24	Motor neuropathies mimicking amyotrophic lateral sclerosis/motor neuron disease. Journal of the Neurological Sciences, 1996, 139, 95-98.	0.6	32
25	The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks. Orphanet Journal of Rare Diseases, 2016, 11, 17.	2.7	31
26	Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations. Neuromuscular Disorders, 2016, 26, 153-159.	0.6	31
27	Two recurrent mutations are associated with GNE myopathy in the North of Britain. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1359-1365.	1.9	30
28	Atypical phenotype in two patients with LAMA2 mutations. Neuromuscular Disorders, 2014, 24, 419-424.	0.6	30
29	Respiratory involvement in ambulant and non-ambulant patients with facioscapulohumeral muscular dystrophy. Journal of Neurology, 2017, 264, 1271-1280.	3.6	30
30	Respiratory disorders in ALS: sleep and exercise studies. Journal of the Neurological Sciences, 1999, 169, 61-68.	0.6	29
31	219th ENMC International Workshop Titinopathies International database of titin mutations and phenotypes, Heemskerk, The Netherlands, 29 April–1 May 2016. Neuromuscular Disorders, 2017, 27, 396-407.	0.6	29
32	Congenital Myasthenic Syndromes with Predominant Limb Girdle Weakness. Journal of Neuromuscular Diseases, 2015, 2, S21-S29.	2.6	28
33	Phenotypic variability of TRPV4 related neuropathies. Neuromuscular Disorders, 2015, 25, 516-521.	0.6	27
34	SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain. Journal of Medical Genetics, 2019, 56, 693-700.	3.2	27
35	Acquired amyloid neuropathy in a Portuguese patient after domino liver transplantation. Muscle and Nerve, 2010, 42, 836-838.	2.2	25
36	Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry. Journal of Neurology, 2016, 263, 1401-1408.	3.6	25

#	Article	IF	Citations
37	Recessive variants of <i>MuSK</i> are associated with late onset CMS and predominant limb girdle weakness. American Journal of Medical Genetics, Part A, 2018, 176, 1594-1601.	1.2	25
38	FSHD type 2 and Bosma arhinia microphthalmia syndrome. Neurology, 2018, 91, e562-e570.	1.1	24
39	225th ENMC international workshop:. Neuromuscular Disorders, 2017, 27, 782-790.	0.6	20
40	Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation. Annals of Clinical and Translational Neurology, 2019, 6, 642-654.	3.7	20
41	Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy. Nature Communications, 2022, 13, 2306.	12.8	20
42	Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy. Orphanet Journal of Rare Diseases, 2022, 17, 23.	2.7	19
43	New transthyretin mutation V28M in a Portuguese kindred with amyloid polyneuropathy. Muscle and Nerve, 2000, 23, 1016-1021.	2.2	18
44	HNRNPDL-related muscular dystrophy: expanding the clinical, morphological and MRI phenotypes. Journal of Neurology, 2019, 266, 2524-2534.	3.6	18
45	Relative frequency of known causes of multiple mtDNA deletions: Two novel POLG mutations. Neuromuscular Disorders, 2011, 21, 483-488.	0.6	16
46	Facioscapulohumeral muscular dystrophy 1 patients participating in the UK FSHD registry can be subdivided into 4 patterns of self-reported symptoms. Neuromuscular Disorders, 2020, 30, 315-328.	0.6	15
47	Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. The EUCERD Recommendations. Blood Transfusion, 2014, 12 Suppl 3, s621-5.	0.4	14
48	Private dysferlin exon skipping mutation (c.5492G>A) with a founder effect reveals further alternative splicing involving exons 49–51. Journal of Human Genetics, 2010, 55, 546-549.	2.3	12
49	Screening for Pompe disease in a Portuguese high risk population. Neuromuscular Disorders, 2017, 27, 777-781.	0.6	12
50	Phenotype may predict the clinical course of facioscapolohumeral muscular dystrophy. Muscle and Nerve, 2019, 59, 711-713.	2.2	12
51	A new mtDNA–tRNAGlu mutation (14728T>C) presenting a late-onset mitochondrial encephalomyopathy. Mitochondrion, 2007, 7, 396-398.	3.4	8
52	Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis. Journal of Neuromuscular Diseases, 2017, 4, 327-335.	2.6	8
53	Evidence for central abnormality in respiratory control in primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 57-60.	2.1	7
54	How the EUCERD Joint Action supported initiatives on Rare Diseases. European Journal of Medical Genetics, 2017, 60, 185-189.	1.3	7

#	Article	IF	CITATIONS
55	Whole-exome sequencing identifies mutations in <i>MYMK</i> in a mild form of Carey-Fineman-Ziter syndrome. Neurology: Genetics, 2018, 4, e226.	1.9	6
56	Genetic testing offer for inherited neuromuscular diseases within the EURO-NMD reference network: A European survey study. PLoS ONE, 2020, 15, e0239329.	2.5	6
57	A case of asymptomatic cytoplasmic body myopathy revealed by sinvastatin. Neuromuscular Disorders, 2009, 19, 66-68.	0.6	5
58	Co-presentation of adult-onset systemic lupus erythematosus and nemaline myopathy. Rheumatology, 2017, 56, 2034-2035.	1.9	5
59	237th ENMC International Workshop: GNE myopathy – current and future research Hoofddorp, The Netherlands, 14–16 September 2018. Neuromuscular Disorders, 2019, 29, 401-410.	0.6	5
60	Intragenic <i>DOK7</i> deletion detected by whole-genome sequencing in congenital myasthenic syndromes. Neurology: Genetics, 2017, 3, e152.	1.9	4
61	Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy. Neuromuscular Disorders, 2018, 28, 965-968.	0.6	4
62	Survey on patients' organisations' knowledge and position paper on screening for inherited neuromuscular diseases in Europe. Orphanet Journal of Rare Diseases, 2021, 16, 75.	2.7	3
63	Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy. Orphanet Journal of Rare Diseases, 2022, 17, 96.	2.7	2
64	Abrupt onset of progressive muscular atrophy. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 61-62.	1.2	0
65	"Double-trouble―or digenic disorder in complex I deficiency. Mitochondrion, 2012, 12, 585.	3.4	0
66	Title is missing!. , 2020, 15, e0239329.		0
67	Title is missing!. , 2020, 15, e0239329.		0
68	Title is missing!. , 2020, 15, e0239329.		0
69	Title is missing!. , 2020, 15, e0239329.		0